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Does drug treatment for depression with selective serotonin reuptake inhibitors (SSRIs) increase or
decrease the risk of completed suicide?  The question is important in part because of recent government
warnings that question the safety of SSRIs, one of the most widely prescribed medications in the world.
While there are plausible clinical and behavioral arguments that SSRIs could have either positive
or negative effects on suicide, randomized clinical trials have not been very informative because of
small samples and other problems.  In this paper we use data from 26 countries for up to 25 years to
estimate the effect of SSRI sales on suicide mortality using just the variation in SSRI sales that can
be explained by cross-country variation in the growth of drug sales more generally.  We find that an
increase in SSRI sales of 1 pill per capita (about a 12 percent increase over 2000 sales levels) is associated
with a decline in suicide mortality of around 5 percent.  These estimates imply a cost per statistical
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  Does anti-depressant drug treatment increase or decrease the risk of completed suicide?    
Since major depression is a leading risk factor for suicide, and because antidepressant drugs are 
generally effective in treating depression [Goldsmith et al., 2002], it might be expected that 
increasing use of antidepressants would reduce suicide.
1  However a number of recent studies 
suggest that the most commonly used class of antidepressant drugs – selective serotonin reuptake 
inhibitors (SSRIs) – might actually increase the risk of suicidal behavior [FDA, 2006, Hammad 
et al., 2006].  One candidate explanation is heterogeneity in psychopharmacological effects:  
some patients might experience a worsening of mood from SSRI treatment.  Another candidate 
explanation comes from the possible behavioral responses of patients and medical practitioners 
to the improved safety and reduced side effects of SSRIs relative to older tri-cyclic 
antidepressants (TCAs), a version of what Viscusi [1984, 1985] terms the “lulling effect.”  In 
response to these recent studies, regulatory agencies in both the US and UK have issued 
warnings about the use of SSRIs first for people under 18 years of age [U.K. Department of 
Health, 2003; FDA 2003, 2004; Goode 2003] and more recently for adults as well [FDA, 2005]. 
This topic is of interest to economists for at least two reasons.  First, it is important.  
Suicide increased dramatically for youth starting in 1950 and is now the third leading cause of 
death among persons age 15-24 in the US [Cutler, Glaeser and Norberg, 2001; Goldsmith et al., 
2002].  Suicide is an important cause of death in all age groups, claiming the lives of around 
30,000 Americans every year and another one million people or so worldwide [Goldsmith et al., 
2002].  Recent estimates suggest the lifetime prevalence of major depressive disorders is on the 
                                                 
1 In their seminal paper Hamermesh and Soss [1974] present a model in which individuals commit suicide if the 
present value of expected lifetime utility is zero. Within their framework SSRIs might reduce suicide by changing 
the technological relationship that determines the cost of maintaining some minimum subsistence quality of life, by 
changing the enjoyment people obtain from any given level of consumption, or improving people’s productivity. 
  1order of 17 percent [Kessler, Berglund et al., 2005].
2  In 2000, SSRIs were the second most 
commonly prescribed drug class in the U.S., and the third best-selling drug class in the world 
[IMS Health, 2006].  Understanding how SSRIs affect suicide is relevant for policy decisions 
about whether to restrict or encourage access to these drugs, and about how to regulate their use. 
A second reason this question is of interest to economists is that the standard empirical 
tools of medical and public health research have not been very informative about the effects of 
SSRIs on the outcome of arguably greatest medical and policy concern – suicide mortality.  
Randomized clinical trials (RCTs) employ sample sizes that are too small to detect effects on 
rare health outcomes such as suicide completion.  As a result most previous studies, and even 
meta-analyses of studies, rely on measures of non-lethal “suicidality,” [e.g., Fergusson et al., 
2005; Hammad et al., 2006], but the association between these indicators and actual suicide 
mortality remains unclear [Cutler, Glaeser and Norberg, 2001; Baldessarini et al., 2006a].  In 
addition the subjects enrolled in RCTs typically exclude subjects at highest risk for suicide, and 
the conditions under which both treatment and control subjects receive treatment in clinical trials 
may differ from the standard level of care provided to patients outside of such trials. The lack of 
evidence about completed suicide has generated intense controversy about the FDA warnings, in 
part because the warnings could create harm by deterring SSRI use among patients who might 
benefit from antidepressant treatment.  As one researcher involved in the FDA review panels told 
the New York Times, “Sitting up there and having the public yell that you’re killing their children 
is no fun.”  A medical historian told the Times “It’s like a religious war,” with a level of 
argument not seen since “the 1960s and 1970s, when scientists were challenging psychoanalysis” 
[Carey, 2006]. 
                                                 
2 These disorders also impose substantial costs on society beyond their impact on suicide, such as by affecting 
human capital accumulation, employment, productivity, crime, child abuse, accidents, homelessness and divorce 
[Frank and McGuire, 2000; Marcotte and Wilcox-Gök, 2001; Currie and Stabile, 2004]. 
  2In principle analysis of population-level data could provide the statistical power needed 
to detect relationships between SSRI use and suicide mortality.  Yet existing epidemiological 
studies have employed weak research designs, typically before-after comparisons using data 
from one or a few countries, which provide limited power to rule out the influence of 
confounding factors.  More recently a few studies have drawn on county- or country-level panel 
data to at least control for shared period effects or time-invariant attributes of these jurisdictions 
[Dahlberg and Lundin, 2005; Gibbons et al., 2005; Ludwig and Marcotte, 2005].  Despite these 
improvements causal inference from these studies remains difficult because variation in SSRI 
drug sales over time and across jurisdictions may be simultaneously determined with changes in 
the prevalence of mental disorders: SSRI sales might increase in response to increases in the 
prevalence of depression.  Even the timing of when SSRIs are approved for sale may be 
endogenous, given that previous studies find time-to-approval is shorter for important drugs that 
treat high-visibility health problems [Dranove and Meltzer, 1994; Carpenter, 2002]. 
  The contribution of the present paper is to provide new empirical estimates for the effects 
of SSRIs on suicide mortality by combining the statistical power associated with analysis of 
population-level data together with a plausibly exogenous source of identifying variation in SSRI 
sales.  Specifically, we construct a panel dataset for 26 countries for up to 25 years, and exploit 
just the variation in SSRI sales across countries over time that can be explained by differences 
across countries in how quickly they usually bring new drugs in general to market, and by 
differences in how rapidly new drug sales typically increase.  We show that differences across 
countries in the rate of sales growth for the other major new drugs that were introduced in the 
1980s for treatment of non-psychiatric health conditions can explain a substantial amount of 
variation in SSRI sales.  This source of variation would not seem to be susceptible to bias from 
  3reverse causation (SSRI sales increase because of increasingly prevalent mental health 
disorders), or from bias due to correlations between adoption of SSRIs and general 
improvements in mental health care systems. 
We estimate that an increase in SSRI sales of 1 pill per capita (around a 12 percent 
increase over 2000 sales levels) would reduce suicide mortality rates by around 5 percent.  These 
estimates imply that around 1 suicide is averted for every 200,000 pills sold.
3  Commonly used 
SSRIs can currently be obtained in the United States for around $0.10 per pill, which suggests a 
cost per statistical life saved from increasing SSRI use of around $20,000 – far below most other 
government regulations or policies to improve health.  A formal benefit-cost analysis requires 
grappling with difficult conceptual and normative questions about how to value safety gains 
among a population at high risk of attempting self injury.  We briefly discuss these important 
issues in the concluding section, although a full treatment is beyond the scope of this paper. 
  A more practical concern with our instrumental variables (IV) research design stems from 
the possibility that countries where new drug sales increase at different rates might differ in other 
ways that are relevant for mental health and suicide.  One way we address these concerns is to 
control for country and year fixed effects and even country-specific linear trends.  We also show 
that our point estimates are hardly affected by also controlling for each country’s population age 
structure, unemployment rate, and real GDP per capita.  The estimates are also quite similar 
when we restrict our analytic sample just to member countries of the Organization for Economic 
Co-Operation and Development (OECD), which may be less dissimilar than our broader sample 
of countries with respect to potential confounding factors. 
                                                 
3 In Table 1 below we show that the mean suicide rate for our sample over the study period is about 10 per 100,000.  
Our point estimate thus implies that an increase in SSRI sales of 1 pill per capita reduces suicide mortality by 
5%*(10 / 100,000) = .000005 deaths per capita.  So an increase in SSRI sales of 200,000 pills would reduce 
mortality by 1 statistical life. 
  4As another specification check we show that our IV estimates suggest no relationship 
between SSRI sales and accident deaths, which should not be affected by SSRI drug treatment.  
Finally, we demonstrate that countries with high versus low rates of growth in drug sales more 
generally experienced very similar trends in suicide mortality during the 1980s, when SSRIs 
were not widely used.  The differences in suicide mortality trends between high- and low-drug-
growth countries are instead concentrated in the 1990s, when SSRI use became widespread. 
The remainder of the paper is organized as follows.  The next section briefly summarizes 
previous empirical work in this area; Section 3 describes our data; Section 4 presents our 
empirical methods and results, and the final section discusses implications of the results. 
II. BACKGROUND 
The concern that antidepressant drugs could increase, rather than decrease, the risk of 
suicide dates back to the introduction of the first tri-cyclic antidepressants (TCAs) in the 1950’s.  
Long before the FDA’s recent “black box” warning for SSRIs, the agency required that 
antidepressant drugs include some standard warning language for patients.
4  There are both 
clinical and behavioral arguments for why TCAs might increase the risk of suicide.  One clinical 
mechanism has to do with the slow therapeutic effects of these drugs.  Most antidepressants 
(including both SSRIs and TCAs) take at least four or more weeks to result in a clinically 
significant improvement in depressed mood.  However, other psychopharmacological effects 
may occur within the first few days of treatment.  As early as the 1960’s, psychiatry textbooks 
warned that the risk of suicide may increase during early phases of treatment because the 
medications may give depressed patients the energy to follow through on a suicidal motive, long 
                                                 
4 “The possibility of a suicide attempt is inherent in major depressive disorder and may persist until significant 
remission occurs. Close supervision of high-risk patients should accompany initial drug therapy. Prescriptions for 
Drug X should be written for the smallest quantity of tablets consistent with good patient management, in order to 
reduce the risk of overdose.” 
  5before they lead to an improvement in mood [FDA 2006].  A second clinical concern stems from 
the possibility of heterogeneity in drug effects across patients.  Specifically, recent studies 
suggest antidepressants might worsen mood in patients with undiagnosed bipolar disorder 
[Baledessarini et al., 2006b].  There is also growing evidence that the effects of antidepressants, 
as well as their side effects, may differ for children, adolescents, and adults [FDA 2006].   
The behavioral mechanism through which antidepressant drugs might increase suicide 
risk stems from the potential of TCAs to be highly toxic in overdose.  As a result, a prescription 
for these drugs might lower the “price” of suicide by providing easy access to an effective 
method of self harm.  This type of “instrumentality effect” would imply that suicide methods are 
not perfectly substitutable and that people at high risk for suicide are at least somewhat 
responsive to the availability of different methods.
5 
A major technological innovation in the treatment of depression (and the focus of the 
present study) occurred in 1984 with the introduction of the selective serotonin reuptake 
inhibitors (SSRIs).  SSRIs are described as “selective” because they affect only the reuptake 
pumps responsible for serotonin, a small molecule that serves as a neurotransmitter, or “chemical 
messenger,” in the brain.  SSRIs increase the amount of the neurotransmitter serotonin that is 
active in the synapses between cells, thereby enhancing neuronal activity and improving mood.  
In contrast to SSRIs, the TCAs affect multiple neurotransmitters.  While the SSRIs seem to be 
similar to the older TCAs in their ability to reduce depression (e.g., Trindade et al. [1998], 
                                                 
5 Suicide methods may not be perfect substitutes in part because of considerable variability in skill required, 
physical pain, likelihood of rescue, likelihood of a fatal outcome, and likelihood of permanent injury if the outcome 
is not fatal. Different methods of suicide are not readily available to everyone at all times – for example, “only” 
around one-third of American households own guns [Cook and Ludwig, 1996], tall buildings or bridges are more 
common in some places than others, and some people are more likely to receive prescription medications than 
others.  Research provides at least qualified support for the idea that changing access to suicide methods – such as 
reduced access to guns, or reducing the carbon monoxide content of domestic gas – may achieve at least temporary 
reductions in suicide [Krietman, 1976; Ludwig and Cook, 2000; Goldsmith et al., 2002; Duggan, 2003]. 
  6Mallick et al., [2003], Ryan [2003], Green [2003], Vaswani et al. [2003]),
6 they are more 
selective in their operation and therefore have fewer physical side effects (such as dry mouth, 
drowsiness, or cardiac arrhythmia) and are less toxic in overdose.    
The introduction of SSRIs may have reduced the population suicide rate in two ways.  
First, SSRIs reduced the “price” of treating depression.  The milder physical side-effect profile 
may increase the willingness of patients to start and continue taking medication, and has also led 
antidepressant drugs to be prescribed for a much wider range of patients by a wider range of 
practitioners [Guze, 1996; Lawrenson et al., 2000].  It is true that some of the increase in SSRI 
use could have been substitution from talk therapy, and current research is ambiguous about the 
relative effectiveness of the two forms of treatment [e.g., Klein, 2000].  But overall SSRIs have 
probably played a role in the increase in the number of people receiving treatment for depression 
in the U.S. [Kessler, Demler et al., 2005; Thorpe et al., 2004]. 
A second mechanism through which SSRIs might reduce suicide comes from the fact that 
SSRIs might partially substitute for the older TCAs.  The lower toxicity of SSRIs relative to 
TCAs could reduce the risk of suicide through an instrumentality effect.  The improved ratio of a 
therapeutic dose to a toxic dose of SSRIs means that an act of intentional self harm by 
swallowing, say, a one-month supply of SSRIs is probably less lethal than swallowing a one-
month supply of TCAs.
7  The introduction of SSRIs might therefore increase the “price” of 
completed suicide, if substitutes for TCAs as a method of relatively “painless” suicide were less 
easily available.   
                                                 
 
7 However, little is known about the actual case fatality rates for overdoses with SSRIs versus TCAs, and it is an 
open question whether persons attempting self harm via overdose are aware of the relative toxicity of one 
medication over another. 
  7However there are also clinical and behavioral arguments to suggest that SSRIs could 
potentially lead to an increase in the risk of suicide to patients using antidepressant drugs and 
overall suicide rates.  The clinical concern stems from the possibility of heterogeneity in 
psychopharmacological effects, and in particular the possibility that the risk of an adverse effect 
of antidepressant drug treatment on mood may be more pronounced with SSRIs than TCAs.  
Even if SSRIs and TCAs had the same effects on suicidal states, the increased prevalence of drug 
treatment following the introduction of SSRIs could have led to an increased number of persons 
at risk for an adverse drug reaction. 
It is also possible that SSRIs could potentially increase suicide risk through a “lulling 
effect” [Viscusi, 1984, 1985].  Economists have long been concerned about the possibility that 
consumers will reduce safety precautions in response to the introduction of new, safer consumer 
products [see for example Peltzman, 1975].  Viscusi’s [1984, 1985] elaboration of this idea 
raises the possibility that improved product safety could increase product injury rates if 
consumers misperceive risks. 
In the case of SSRIs the increased safety of these drugs relative to TCAs may have led a 
broader (and perhaps less experienced or qualified) set of health practitioners to be willing to 
provide drug treatment for depression, and may also have led payers, clinicians, and patients to 
accept a shortening of in-patient hospital stays and reduction of intensity of outpatient treatment
8 
with a consequent drop in the vigilance of patient monitoring.  In many countries there have been 
dramatic changes in the locations of psychiatric service provision over the past 40 years, with 
state psychiatric hospitalization being replaced by treatment in community settings.  The 
development of safer and more effective drug treatments is thought to have contributed to this 
                                                 
8 Many studies find that a combination of drug treatment and psychotherapy is more effective than either treatment 
alone [eg, March et al., 2004], so SSRIs might increase the risk of suicide among those patients who would formerly 
have been referred for more intensive treatment and supervision. 
  8shift in the location of care.  But there is a long history of concern that the deinstitutionalization 
process may have led to a higher suicide rate [e.g. Hansen et al., 2001; Flechner, Wolf and 
Priebe, 1995; Salzer et al., 2006] for much the same reasons that improved product safety could 
increase the risk of product injury rates if consumers (or clinicians or policy makers) have 
misperceived the actual risks.  While little is known about perceptions of the risk of SSRI use or 
overdose, it is possible that the risk of death from overdose with SSRIs is low enough (either 
absolutely or relative to that of TCAs) so that users or providers engage in what Kahneman and 
Tversky [1979] call “editing” and ignore these risks altogether [see also Kunreuther, 1978].
9 
Another “lulling effect” might stem from the fact that some self-injury attempts may be 
motivated by reasons other than the desire to end life, including to signal for help, punish family 
or friends, or secure resources more generally [Rosenthal, 1993; Cutler, Glaeser and Norberg, 
2001; Marcotte, 2003].  The introduction of a safer overdose alternative – SSRIs – could 
paradoxically lead to an increase in the number of suicide attempts, thus increasing the number 
of unintentional deaths resulting from self-injury attempts without lethal intent. 
The question of whether antidepressant drugs might actually increase suicide risk first 
came to national attention in 1990, with the publication of a report describing six adult patients 
who apparently became suicidal as a result of being treated with fluoxetine (Prozac). The 
ensuing debate led the FDA to review the issue, with hearings in 1991.  A review of all of the 
clinical trials conducted by the manufacturer revealed no sign of increased suicidality associated 
with the use of Prozac [Beasley et al, 1991]. 
Over the next several years, as newer drugs came to market, pooled analyses of 
individual clinical trials were updated in order to search for possible signs of risk.  In May of 
                                                 
9 This is also in some ways analogous to what Akerlof, Dickens and Perry (ADP) [2000] argue workers and firms 
might do in low-inflation environments.  ADP also note that the salience of an event might also be relevant in 
whether individuals pay attention versus ignore some factors; see for example Gleitman [1996]. 
  92003, GlaxoSmithKline reported an increased risk of suicide-related adverse events in a pediatric 
trial of paroxetine (Paxil). This led to an analysis of all available pediatric trials, and finally to an 
FDA “black box” warning of increased risk of suicidal behavior associated with antidepressant 
use in pediatric patients. Since then, the FDA has commissioned several large pooled studies, the 
first covering pediatric clinical trials of new antidepressants, and the most recent covering adult 
trials. Taken together, these studies have found a plausible and statistically significant 
association between assignment to SSRI (versus placebo) and non-lethal suicidal behavior in 
adolescents [Hammad et al 2006] and in young adults, as well as a statistically significant 
decrease in suicidal ideation and behavior from drug treatment in older adults [FDA 2006].  
There are several reasons why RCTs will have difficulty identifying the relationship 
between SSRIs and the outcome that is arguably of greatest medical and policy concern – 
completed suicide.  The most important limitation of the clinical trial study is sample size: even 
studies with the largest pooled RCT samples have had sample sizes too small to detect 
differences in important but rare outcomes such as suicide [Deyo, 2004].  For example, a recent 
meta-analysis involving a total of 87,650 patients found just 24 completed suicides, and so relied 
on an outcome measure that pools together fatal and non-fatal attempts [Fergusson et al., 2005].  
This study found a statistically significant increase in the risk of (lethal plus non-lethal) suicide 
attempts for patients receiving SSRIs compared to placebo, and no difference in the risk of 
suicide attempts between patients receiving SSRIs and tricyclic antidepressants.  However as 
Baldessarini et al. [2006a, p. 246-7] note, only a small fraction of patients with suicidal thoughts 
attempt suicide, few attempts prove to be fatal, and, importantly, the risk factors for suicide 
attempts versus completions differ markedly [see also Cutler, Glaeser and Norberg, 2001]. 
  10The second problem with RCTs is that the participants who are enrolled may be 
unrepresentative of the average patient. For ethical and practical reasons, most clinical trials 
avoid enrolling subjects with prior histories of suicide attempts or current histories of suicidal 
ideation [Pearson et al., 2001].  As a consequence, these studies exclude those people at highest 
risk for suicide [Goldsmith et al., 2002; Zimmerman et al, 2002; Baldessarini, 2005; Ferguson et 
al., 2005, Baldessarini et al., 2006a; Khan et al., 2000, 2001].  In addition the type of treatment 
offered in RCTs may be unrepresentative of the usual community levels of care. For example, 
they may take place in academic medical centers and outpatient settings, with structured 
protocols and better staffing than may be available in non-academic mental health settings. A 
final problem is that most new drug trials involve comparisons between the new drug and 
placebo, but providers and policy analysts may also be most interested in the comparison 
between newer drugs and those already on the market. 
  To study questions that cannot be addressed by RCTs, investigators have used a variety 
of “non-experimental” research designs. However, most previous population-based studies of 
SSRIs and suicide have used research designs with limited power to rule out the influence of 
competing explanations.  Specifically, most of these studies have simply compared suicide rates 
before and after SSRIs become available in a particular jurisdiction.  Studies of Sweden, Finland, 
Norway, Hungary and Australia using this “interrupted time series” design have found that 
suicide rates declined as SSRI use increased [Isacsson, 2000; Rihmer et al., 2001; Ohberg et al., 
1998; Hall et.al., 2003], although a study in Italy found no effect [Barbui et al., 1999].  Yet the 
independent effects of SSRI use are difficult to infer from studies that rely on simple before-and-
after comparisons within a given country. The overall problem with this study design is that it 
cannot distinguish the effects of the policy change – in this case, the introduction of SSRIs – 
  11from the effects of other factors such as deinstitutionalization that might be changing over the 
same time period. 
  One way to improve on this before-and-after design is to compare suicide outcomes 
across multiple jurisdictions that have changed their policies regarding SSRI use at different 
times in a standard fixed-effects setup with panel data.
10  Two studies have used this approach to 
examine variation in SSRI sales across jurisdictions over time within a single country.  Using 
data for the U.S. for the years 1996 to 1998, Gibbons et al. [2005, 2006] find that increases in 
prescriptions for SSRIs and other newer anti-depressants are associated with lower suicide rates 
both within and between counties, including for children and adolescents.  The authors note that 
this is consistent with anti-depressant efficacy and low toxicity in the event of a suicide attempt, 
but also with the possibility that local SSRI sales levels may be positively correlated with the 
quality of local mental health care.  Dahlberg and Lundin [2005] examine variation in SSRI sales 
across counties and age groups in Sweden, and find no significant association between SSRI 
sales and suicide rates. 
A third study using this same basic approach examines variation in use of SSRIs across 
countries over time.  Ludwig and Marcotte [2005] use data from 27 countries over 20 years, and 
condition on country-specific linear trends as well as country and year fixed effects.  They find 
that an increase in SSRI sales of one pill per capita is associated with a 2.5 percent decline in 
suicide rates.  That study serves as the launching-off point for the current research. 
The obvious concern is that even standard “fixed effects” estimates that compare trends 
across countries over time may be susceptible to bias from other unmeasured factors that affect 
both changes in SSRI use and suicide mortality.  For example, if countries try to improve access 
                                                 
10 A different approach adopted by Jurrlink et al. [2006] is to use individual-level data from medical records and 
compare suicide rates for those who receive SSRI treatment versus others, using propensity-score matching methods 
to control for selection into SSRI treatment on the basis of observable background characteristics. 
  12to psychiatric medications in tandem with other improvements to their mental health systems, a 
standard panel-data analysis may overstate any socially beneficial effect of SSRIs on suicide 
mortality.  Alternatively, the movement towards deinstitutionalization, or other forces leading to 
increases in the prevalence of mental health problems, may have driven increased anti-depressant 
drug sales, or caused government regulators to bring SSRIs to market sooner.
11  In this case, any 
beneficial effect of SSRI sales on suicide risk might be masked by the positive correlation 
between suicide rates and market demand for drug treatment of depression. 
In the present study, we seek to overcome this source of bias by using a research design 
that relies on just the variation in SSRI sales that can be predicted from the rate of growth in 
sales of the major non-psychiatric medications that were introduced over the same time period 
(the 1980s) in which SSRIs were introduced.  The next section describes our data while the 
subsequent section discusses our methods and findings. 
III. DATA 
In this paper we examine country-level data in order to take advantage of both the 
statistical power of population data for studying suicide mortality and the variation across 
countries in both the levels and trends of sales of SSRI and other drugs. 
Annual data on suicide mortality is widely available for a large sample of countries from 
the World Health Organization (WHO), which in turn obtains these data from national vital 
statistics reporting systems.  Data for each country include the annual number of total suicides 
and by gender and age, as well as relevant population counts.  We have these data for at least 
1980 through 1999 for all countries, and have been able to extend the panel through at least 2000 
for about half of our countries.  Most of these suicide reports were recorded by local medical or 
                                                 
11 Previous research suggests that more important drugs that address more high-visibility health problems seem to be 
approved by the FDA more quickly [Kaitin et al., 1991 ; Dranove and Meltzer, 1994 ; Carpenter, 2002]. 
  13public health officials using the International Classification of Diseases, 9
th Revision (ICD-9) 
system for coding cause of death, although by the end of the panel some countries use the newer 
ICD-10.  While data from the United States suggests that both coding schemes capture suicides 
in a consistent fashion [Anderson et al., 2001], in our analysis we accounted for the possibility 
that a shift from ICD-9 to ICD-10 may produce changes in recorded suicide rates in some 
countries within our sample.  Our analytical methods also account for the possibility of fixed 
cultural or institutional differences across countries in how suicides are officially recorded. 
The main constraint on the construction of our country-level sample is the availability of 
data on SSRI sales.  Our core analytic sample consists of the 26 countries for which we have 
been able to obtain annual SSRI sales data from IMS Health, Inc., a commercial firm that 
provides data on international pharmaceutical sales to manufacturers and health care providers.  
The diverse set of countries in our main analytic sample are:  Argentina; Australia; Austria; 
Belgium; Brazil; Canada; Chile; Columbia; Ecuador; Finland; France; Greece; Ireland; Israel; 
Italy; Japan; Luxembourg; Mexico; Netherlands; New Zealand; Norway; Portugal; Spain; United 
Kingdom; United States; and Venezuela.  One possible concern is that our sample of countries is 
too diverse, although we demonstrate below that our results are similar when we restrict attention 
to just member nations of the Organization for Economic Co-Operation and Development 
(OECD).
12  We exclude countries that transitioned from Communist to other forms of 
government during our sample period (including Germany) to avoid confounding the 
introduction of SSRIs with the profound social changes that accompanied these transitions.
13  
                                                 
12 This restriction drops Argentina, Brazil, Chile, Colombia, Ecuador, Israel, and Venezuela. 
13 For example in the Ukraine suicide mortality rates per 100,000 declined steadily from 1981 to 1991 from 23.7 to 
20.5, but following the replacement of the USSR by the Commonwealth of Independent States in 1991, when 
Ukraine became an independent country, suicide rates increased steadily and by 2000 equaled 29.3, perhaps related 
to increases in heavy drinking [Webb et al., 2005].  For Germany the challenge is that we cannot obtain annual 
suicide mortality data for East Germany prior to 1989; in that year suicide rates per 100,000 are more 1.5 times as 
  14Another practical motivation for excluding former Communist countries is limited availability of 
data on drug sales, and in some cases also limited data on suicides in the pre-transition period.  
  For each of these countries we have information about drug approval dates back to 1980 
for all SSRIs, which includes fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram and 
venlafaxine.  We have also been able to obtain data on actual SSRI sales for these countries for 
each year back to 1990.  The fact that we do not have SSRI sales data before 1990 could in 
principle complicate our analysis, although it is important to note that most countries began to 
sell SSRIs starting only in the late 1980s and in almost all countries SSRI sales growth was a 
phenomenon of the 1990s (see Table 1).  For countries that approved SSRIs before 1990 we do 
know what sales were in the years before approval – zero.  We use linear interpolation to impute 
sales in years between the date of SSRI approval and 1990.
14  More complicated imputation 
procedures are possible, but we show below that our results are not sensitive to how we address 
this problem since we obtain nearly identical results when we set to missing those country-year 
observations in the 1980s that come after SSRIs had been approved in a country. 
To implement our preferred IV strategy below, we also obtained similar information from 
IMS Health about drug introduction dates and sales data for four drug classes other than SSRIs.  
We selected drugs that satisfied three criteria:  (1) Like SSRIs, they must have been introduced 
in the 1980s so that the set of institutions that generally affect the drug adoption process are 
similar across drug types; (2) Like SSRIs, they must have been among the top-ten selling drug 
classes at the end of our study period (1998-2000), in the event that there is some general “major 
drug” effect on regulatory approval or sales trends; and (3) Unlike SSRIs, these drugs should not 
                                                                                                                                                             
high in East versus West Germany (25.8 versus 16.5).  Using data just on West Germany over our study period is 
problematic in part because of increased migration of East Germans into the West following reunification. 
14 Specifically for each country we know sales in the year before approval (zero) and from our data sales levels in 
1990, and then just linearly interpolate SSRI sales data in the intervening years. 
  15be used in the treatment of psychiatric illnesses, to avoid the potential endogeneity problems 
described above. The drug classes that satisfy these criteria are summarized in Table 2:  Statins, a 
class of drugs designed to lower LDL (“bad”) cholesterol; proton pump inhibitors (PPIs), which 
are used to treat stomach and duodenal ulcers; and two drug classes used to treat hypertension, 
calcium channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors.
15  
Below we describe how we use information on the introduction and rates of sales growth for 
these drugs to construct our instruments. 
In our analyses we also controlled for a number of socio-demographic factors thought to 
affect suicide rates.  For example there is a powerful age structure to suicide mortality (Table 1), 
and so we control for the annual distribution of each country’s population across different age 
groups.  We also have data on unemployment rates from the OECD, and data on real per capita 
gross domestic product adjusted for changes over time in exchange rates [World Bank, 2006]. 
IV. FINDINGS 
  Our preferred estimates, which use just the variation in SSRI sales across countries over 
time that can be explained by variation in the rate of growth in sales of other drugs, suggest that 
an increase in SSRI sales of 1 pill per capita reduces suicide mortality by around 5 percent.  This 
negative relationship is larger in absolute value among relatively younger people, although our 
estimates for age-specific impacts of SSRI sales are limited by the fact that we have data on 
suicide mortality but not SSRI sales broken out separately by age groups. 
A. OLS Results 
Before we present our preferred IV research design and findings, it is useful to have some 
basic understanding of our data and the nature of the variation in both SSRI sales and suicide 
                                                 
15 We were only able to obtain sales data for these drugs back to 1994, and so linearly interpolate annual sales 
figures for countries for the years between when the country first approved the drug for sale and 1994 (in cases 
where countries approved the drugs before 1994). 
  16mortality across countries over time.  As a point of departure, consider the time series of log 
suicide rates and SSRI sales per capita for the OECD countries in our sample from 1980 to 2000 
(Figure 1).  Consistent with the hypothesis that SSRIs may reduce suicide we find a decline in 
suicide mortality in this sample of countries starting in the mid-1990s, about when SSRI sales 
increase dramatically.  However this is something less than definitive proof given the data also 
show some changes in suicide mortality early in the period before SSRIs were on the market.
16 
  Some additional insight into what is going on in the data comes from estimating equation 
(1), where Yit equal to the natural log of country i’s suicide rate per 100,000 people in year t, and 
SSRIit is the number of SSRI pills sold per capita in country i in year t.  We control for the share 
of the population in different age groups (15-24, 25-34, 35-44, 45-54, 55-64 and 65 and up), an 
indicator for whether the country records deaths in that year using the ICD-10 versus -9 system, 
and country and year fixed effects di and dt and country-specific linear time trends, Timet×di.
17 
(1) Yit = a0 + a1 SSRIit + a2 Xit + di + dt + (Timet×di) + v1it 
  Equation (1) is estimated using population-weighted least squares.
18  Estimation without 
population weights generates very similar point estimates but, as we would expect, slightly larger 
                                                 
16 The specific increase in the early 1980s observed in Figure 1 is probably driven by changes in suicide in several 
countries during a period of economic recession.  Another contributing factor is the increase in suicide rates in 
Mexico from extremely low initial levels up closer to international norms, which presumably reflects some declining 
stigma of suicide in that predominantly Catholic country. 
17 The raw data suggested that these country-specific linear terms may be important given differences in trends even 
before SSRI use became widespread.  For example, in Austria the suicide rate declined from 25.4 per 100,000 in 
1980 to 23.3 by 1990 and 18.1 by 2001.  In contrast, the suicide rate in Mexico increased steadily from 1.4 per 
100,000 in 1980 to 3.8 by 2001. The rise in suicide rates over the panel for Mexico may reflect a change in 
reporting, rather than real patterns of mortality, due to a declining stigma associated with suicide.  Other 
predominantly Catholic countries (Ireland, Spain, Italy) saw similar patterns.   
18 The signal-to-noise ratio of country-level suicide rates seems to be higher for larger countries.  For example the 
suicide rate per 100,000 in the U.S. changes modestly year to year (from 1980 to 1985 the annual rate 11.9, 12.0, 
12.2, 12.1, 12.4, 12.4).  The year-to-year variability is much larger in Luxembourg (12.8, 16.7, 21.3, 21.9, 18.6, and 
14.8).  Another way to see this comes from dividing countries in our sample up those with populations above versus 
below the median, then calculating residualized log suicide rates where we take out country-specific linear trends for 
1980-2000.  The variance of the residuals for large vs. small countries is .06 vs. .12. 
  17standard errors.  To account for serial correlation we calculate standard errors that are clustered 
at the country level [Bertrand et al., 2004].
19 
Most of the variation in suicide mortality rates is across countries rather than over time.   
Country fixed effects account for around four-fifths of the total variation in log suicide rates in 
our panel.  These persistent differences in suicide rates across countries are thought to be due to 
in part to climate, culture, urbanicity, and perhaps differences in data recording practices [Smith 
et al., 1995; Goldsmith et al., 2002, Chapter 6].  Country and year fixed effects plus country-
specific linear trends account for 90 percent of the variation in log suicide rates in our panel. 
Table 3 shows countries that experienced relatively larger increases in SSRI sales over 
our study period also experienced relatively larger declines in suicide.  When we regress log 
suicide rates against SSRI sales and country and year fixed effects (column 1), an increase in 
sales of 1 pill per capita (about 12 percent of the mean 2000 sales levels in our sample) is 
associated with a reduction in suicide of around 3.5 percent.  Figure 2 provides some additional 
intuition about this estimate by plotting for each country the change in log suicide rates from 
1980-95 against the change in SSRI sales.
20  We can also see the substantial variation in the 
growth of SSRI sales across countries.  For example SSRI sales increased about twice as much in 
the US as in the UK, while by 1995 Japan had not even introduced SSRIs for sale yet.  Of course 
countries may experience different trajectories in suicide rates for a variety of reasons other than 
SSRI sales.  The second column of Table 3 shows that controlling for population age structure 
                                                 
19 Hansen [2006] shows that standard errors calculated in this way may be overly conservative compared to more 
efficient generalized least squares estimates.  Since our main IV estimates below are statistically significant with the 
more conservative approach, we present clustered standard errors throughout the paper for simplicity.   
20 Even though we have suicide and SSRI sales data through at least 1999 for all of the countries in our sample, with 
our IV design described below we lose some country-years’ of data after 1995, and so for consistency in these 
figures we focus here on the 1980-95 period.  Re-doing Figure 2 using data through 1999 yields a similar picture. 
  18reduces the magnitude of the point estimate by around one-third.  Adding country-specific linear 
trends (column 3) has only a modest impact on the magnitude of our point estimate. 
The larger concern with these OLS estimates is that SSRI sales may be endogenous to the 
conditions that influence suicide.  For example, increases in major depressive disorder could 
drive up SSRI sales.  Since reliable longitudinal, population-level estimates for the prevalence of 
severe depressive disorder are not available for our sample of countries, OLS estimates may 
understate in absolute value any beneficial effect of SSRIs on suicide.  On the other hand, 
countries might expedite approval of SSRIs or implement policies designed to improve access to 
SSRIs as part of a larger portfolio of efforts designed to improve mental health, in which case 
OLS would overstate the protective effects of SSRI on suicide mortality. 
Some indication that these concerns may be empirically relevant comes from the fact that 
there is much more variation across countries in how quickly they approve SSRIs for public sale 
compared to how quickly these countries approve other drugs.  The vertical axis in Figure 3 
shows the number of years that each country actually had SSRIs for sale as of 1995 (note SSRIs 
were first approved for sale anywhere in the world market in 1984).
21  The horizontal axis shows 
how many years SSRIs would have been on the market as of 1995 if each country had approved 
SSRIs as quickly as they approved the other major new drugs introduced in the 1980s (from 
Table 2, Statins, PPIs, CCBs, and ACEs).  That is, for each country we calculate the average 
adoption lag for Statins, PPIs, CCBs and ACES (most countries in our sample approved these 
drugs within a year or two of when they were introduced to the world market), and then calculate 
each country’s predicted approval date for SSRIs as the year SSRIs first came on the world 
                                                 
21 SSRIs were first sold anywhere in the world in West Germany in 1984, which is dropped from our sample as 
described in Section III because of the effects of reunification on suicide in Germany plus the difficulty of obtaining 
reliable data on suicides for East Germany prior to this period. 
  19market (1984) plus the country’s average adoption lag for these four other drugs.
22  Most 
countries in our sample approved these drugs within a year or two of when they were introduced 
to the world market.  The extra variability in the timing of SSRI approval compared to other 
drugs suggests regulators may have had special concerns about these anti-depressant drugs or 
about the underlying health problems they are designed to address. 
In fact we find some evidence suggesting that countries with increasing suicide rates may 
have been quicker to approve SSRIs for public use, as shown in the fourth column of Table 3.  
We re-estimate our basic panel-data setup as in equation (1) but now add a set of indicator 
variables for each of the five years before SSRIs were first sold in each country.  We find that 
these pre-SSRI year indicators are jointly significant (p<.01) and become less negative (smaller 
in absolute value) as we get closer to the time SSRIs were approved. 
One possible concern with this specification check is suggested by Wolfer’s [2006] 
observation that in some applications jurisdiction-specific linear trends could pick up un-
modeled dynamic policy responses in addition to picking up differences across areas in pre-
existing trends, which could bias our coefficient estimates for the indicators for pre-SSRI years.  
Some protection against this concern comes from the fact that our key explanatory variable of 
interest in these OLS models is actual SSRI sales, rather than a simple indicator for SSRIs being 
on the market.  In any case we obtain similar results when we re-run our specification test 
                                                 
22 There are many cultural and institutional reasons why drug approval times might vary across countries.  To take 
just one example, the U.S.  Prescription Drug User Fee Acts (PDUFA) was intended to provide additional resources 
to FDA to speed up drug approvals by charging drug companies user fees. User fees from drug companies vary 
considerably – for example the United Kingdom’s Medicine and Healthcare Products Regulatory Agency receives 
100% of funding from user fees, while Japan’s Koseisho regulatory agency does not charge any user fees [Berndt et 
al., 2005].  Sociological factors may also influence patterns of technology adoption. For example, Skinner and 
Staiger [2005] found that some states in the US consistently adopted effective new technologies, whether hybrid 
corn, tractors, or heart attack treatments, earlier than other states. They also found that early adoption was closely 
associated with social capital and state-level 1928 high school graduation rates, but not per capita income, density, 
or (in the case of Beta Blockers) expenditures on heart attack patients. 
  20without country-specific linear trends, or replace the SSRI variable with a series of indicator 
variables for the number of years SSRIs were on the market. 
It is more difficult to generate a similarly transparent test for the endogeneity of SSRI 
sales growth once these drugs are on the market, though there is ample reason to be worried 
about simultaneity with trends in SSRI sales and mental health conditions.  These conceptual 
concerns together with the empirical findings above motivate the IV analysis that follows. 
B. Main Findings 
  Our preferred research design seeks to identify the effect of SSRIs on overall suicide 
mortality using just the variation in SSRI sales across countries over time that can be explained 
by differences across countries in the timing of when new drugs are approved more generally, 
and the general rate at which sales of new drugs increase once they are on the market.  The 
variation in SSRI sales that can be explained by variation in sales for other drugs is plausibly 
orthogonal to pre-existing trends in mental health conditions or mental health treatment 
environments across countries.  The preferred model is given by the system: 
(2)  it i t t i it it it v d Time d d X b SSRI b b Y 2 2 1 0 * + + + + + + =  
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  As in OLS equation (1) Yit represents the log suicide mortality rate per 100,000 in country 
i in year t, and SSRIit is the actual SSRI sales (pills per capita) observed in each country each 
year.  Our instruments, PSALES(k)it, equal the predicted level of sales of SSRIs in country i in 
year t in the k
th year we predict SSRIs to have been in the market if the country had approved 
SSRIs as quickly as the country approved the four other major new drugs introduced in the 1980s 
that are not used to treat mental health conditions (Statins, PPIs, CCBs, and ACEs), and then 
assuming that the SSRI sales grow each year they are on the market at the same rate as these 
  21other drugs.  Put differently, our instruments represent the counterfactual SSRI sales pattern we 
would have expected in these countries if SSRI sales followed the same introduction and sales 
patterns observed for other drugs. 
  Mechanically, our instruments are constructed as follows.  We begin by calculating the 
predicted SSRI adoption lag for each country (P_Lagi), defined as the average adoption lag for 
each country for the four instrument drugs (Statins, PPIs, CCBs, ACEs) which are indexed by d.  
In equation (4) launchd equals the year in which drug d was first sold (or “launched”) anywhere 











  Then for each country and calendar year we calculate the number of years we predict 
SSRIs would have been on the market if the SSRI adoption lag for that country was the same as 
the average adoption lag observed for the four instrument drugs.  That is, Predicted_Yearit equals 
the year in which SSRIs were first sold anywhere in the world (launchSSRI) plus the country’s 
average adoption lag for the four instrument drugs (P_Lagi).  For example, the U.S. approved 
Statins, PPIs, CCBs and ACEs on average one year after they were introduced anywhere on the 
world market.  Since SSRIs were first launched on the world market in 1984, for the U.S. 
Predicted_Yearit =1 in 1985, Predicted_Yearit =2 in 1986, and so on for each of the k years 
SSRIs would have been for sale in each country.  This is a bit earlier than the first year SSRIs 
were actually sold on the American market, 1988. 
(5)   )} _ ( 1 , 0 max{ _ i SSRI it Lag P launch t Year Predicted + − + =  
Then for the k
th year we predict SSRIs to have been on the market in a given country, our 
instruments, PSALES(k)it, equal the average sales of Statins, PPIs, CCBs, and ACEs in the k
th 
  22year that these drugs were on the market in country i.  So for example for the U.S. when 
Predicted_Yearit =1 in 1985, PSALES(1)it equals the average sales of Statins, PPIs, CCBs and 
ACEs in their first years on the American market, and is equal to zero in all other years.  In 1986 
when Predicted_Yearit =2 the value of PSALES(2)it is the average sales of our four instrument 
drugs the second year they were on the American market, and so on. 
(6)  ) ( 1 ]
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In principle we could calculate a single instrumental variable equal to the predicted 
profile of SSRI sales had they been adopted at the same rate and then had sales growth similar to 
our other instrument drugs.  However that would assume the relationship between sales of other 
drugs and sales of SSRIs would be constant (that is, from equation 3 above, δk=δ for all values of 
k>0).  However, from Table 1 it is clear that SSRI sales growth was initially quite slow, which 
was not typical of the instrument drugs.  Countries with more rapid growth in our instrument 
drugs will be predicted to have faster growth in SSRIs, but this more flexible setup allows for the 
fact that the sales trajectory of SSRIs may be different from that of our other drugs by allowing 
the instruments for each year we predict SSRIS to be on the market to have a separate coefficient 
in the first-stage regression against actual SSRI sales.  In any case as shown below, when we 
instead use just a single instrument for predicted drug sales we lose some first-stage explanatory 
power relative to our preferred model, but the second-stage point estimate is similar to that from 
our preferred model and still statistically significant. 
  Figure 4 provides some intuition by plotting actual SSRI sales each year from 1980 to 
1999 (given by the shaded bars), our instruments (light bars), and the predicted value of SSRI 
sales each year (triangles) for the U.S. and Japan.  As noted above if the U.S. had approved 
SSRIs at the same rate as for our instrument drugs, the first year SSRIs would have been on the 
  23market in America would have been 1985, instead of the actual year of 1988.  The height of the 
light bar for the U.S. in 1985 represents the value of PSALES(1)it for the U.S. in 1985 (i.e. the 
average sales level of our four instrument drugs the first year they were on the American 
market), while the height of the light bar for 1986 is the value of PSALES(2)it for that year.  The 
top panel of Figure 4 shows that the sales trajectory for the four instrument drugs in America was 
steeper in the early years after they were on the market compared to the sales trajectory for 
SSRIs, which is reflected in the predicted SSRI sales value that we calculate from our first stage. 
  The bottom panel of Figure 4 shows that Japan is generally a bit slower than the U.S. in 
approving new drugs [Currie, 1993] but still approved our four instrument drugs on average 
within two years of their introduction anywhere in the world market.  However Japan was much 
slower in approving SSRIs for sale, and in fact did not approve SSRIs for sale until 1999 – fully 
15 years after they first came on the world market.
23  Comparing the top and bottom panels of 
Figure 4 also highlights the fact that most of the variation with our instruments will come from 
differences across countries in the rate of drug sales growth once new drugs are on the market, 
rather than differences in the timing of when new drugs are generally are first introduced for sale 
in our countries.  This also follows logically from the evidence in Figure 3 showing that most 
countries in our panel are relatively rapid adopters of new drugs, and so there is relatively little 
variation across our sample in the predicted date of SSRI adoption. 
The first column of Table 4 shows our first-stage coefficients, which are positive as 
expected – countries with higher rates of growth in new drugs in general have higher rates of 
growth in SSRI sales as well.  The first-stage F-test on our excluded instruments is equal to 29.2 
                                                 
23 Why approval of SSRIs was so delayed in Japan is not clear, but the stigma associated with depression is 
especially severe in Japan [Desapriya and Nobutada, 2002].  The eventual approval of SSRIs in 1999 may have been 
hastened by industry pressure [Kubota, 1997], or by an exceptional 50%  increase in suicide rates during the 1990s, 
a period when virtually all the developed world saw suicide rates fall [Koo and Cox, 2006]. 
  24(p<.01).  Given that we have a relatively large number of instruments (15), Hansen, Hausman 
and Newey [2005] suggest that the concentration parameter may be a better indicator for first-
stage explanatory power, which in our case is equal to 15×(F-1)=422.9.  Hahn and Hausman 
[2002] suggest an alternative test for weak instruments that is essentially based on a comparison 
of IV estimates run “forward” versus “backward” (i.e. switching the dependent variable and 
endogenous explanatory variable, then rescaling the latter appropriately).  If the two sets of 
estimates are significantly different then 2SLS may be inappropriate, although in our application 
we do not reject this null hypothesis at the usual 5 percent cutoff. 
The second column of Table 4 shows that the IV estimates from our second-stage 
equation suggest that an increase of 1 SSRI pill per capita reduces suicide rates by around 5 
percent, which is statistically significant at the usual cutoff.  That our preferred IV estimate is 
somewhat larger in absolute value compared to the naïve panel-data estimates shown in Table 3 
is consistent with the idea that variation in actual SSRI sales may be driven in part by worrisome 
trends within these countries with respect to suicide mortality or negative mental health 
conditions generally, although a standard Hausman test [1978] shown in the last row of the table 
does not allow us to quite reject the null hypothesis that our OLS and IV estimates are equal 
(p=.11).  For purposes of interpretation, a one pill per capita increase in SSRI sales represents 
about a 12 percent increase over the average 2000 sales level across our sample of countries.  An 
increase of one pill per capita also represents a 41 percent increase over average sales over our 
entire sample period, so that the estimated elasticity of suicide with respect to SSRI sales implied 
by the results in Table 4 is equal to around -.12.
24 
                                                 
24 When we replicate our IV estimates and include indicator variables for each of the five years before we predict 
SSRIs to first be sold in each country, we find these indicators are not statistically significant.  However this is not a 
very powerful test because there is so little variation across our countries in the predicted timing of when SSRIs 
  25C. Sensitivity Analyses 
  In general our results seem fairly robust to alternative model specifications and changes 
in our analytic sample.  For example our findings are not driven by the experiences of just a few 
outlier countries.  This is easiest to see from a visual inspection of the difference-in-difference 
analog to our preferred IV estimates (Figure 5).  The horizontal axis shows the change in the 
predicted value of SSRI sales from 1980 to 1995 for each country from equation (4) above, 
while the vertical axis shows the simple change in log suicide rates over the same period.  The 
simple bi-variate relationship between change in log suicide rates and change in predicted SSRI 
sales is negative, consistent with the results of our preferred IV analysis, and does not visually 
appear to be driven by the experiences of outlier countries.    More formally in Table 5 we re-
estimate our preferred IV model excluding different countries that Figure 5 suggests might exert 
special leverage over the regression line (namely the U.S., Mexico, and Japan) and obtain similar 
results.  The second column of Table 5 shows that qualitatively similar results hold when we 
restrict the analytic sample just to member nations of the OECD in our sample.  
  The remainder of Table 5 shows the results are qualitatively similar to a variety of other 
changes in our estimation approach, including dropping country-year observations in the late 
1980s when SSRI sales were imputed, excluding our controls for population age structure and 
ICD-10 coding, or adding in controls for each country’s unemployment rate and/or real GDP per 
capita.  Our panel is a bit unbalanced because the amount of data available on our instrument 
drugs varies a bit across years,
25 but replicating our analysis on a balanced panel using data just 
                                                                                                                                                             
would first be sold if each country’s adoption lag for SSRIs was similar to the average adoption lag for Statins, PPIs, 
CCBs and ACEs.  
25 We have sales data through at least 1999 for all countries, and for a few additional years for a sub-set of our 
sample.  In addition because there is a bit of variation across countries in when they approved our four instrument 
drugs for sale the number of years-on-the-market for which we can calculate our instruments will vary slightly 
across countries.  As a result our standard IV estimates drop some country-year observations in the late 1990s. 
  26through 1997 yields similar results.  While our main estimates weight by country population, the 
un-weighted point estimate is similar although somewhat less precisely estimated.  Re-
calculating the estimates using actual rather than logged suicide rates yields a point estimate of -
.24, which given an average suicide rate of 10.2 in our panel (Table 1) implies that an increase in 
SSRI sales of 1 pill per capita reduces suicide by around -2.5%, about half the size of the log 
specification and now no longer statistically significant.  However given the substantial 
differences in suicide levels across countries described above a log-linear model that estimates 
SSRI impacts in proportional rather than absolute terms seems preferable. 
Our preferred model uses separate instruments for each of the (k) years drugs are on the 
market to allow the shapes of the trajectories of sales growth for our instrument drugs to differ 
from the trajectory of SSRI sales (consistent with inspection of Figure 4).  When we restrict the 
first-stage coefficient of other drug sales on SSRI sales to be the same regardless of how long 
drugs have been on the market (i.e., we replace our series of variables for other drug sales in the 
k
th year they are on the market with a single linear term for other drug sales), the first-stage 
explanatory power of our instrument set declines (F=21.2, versus 29.2 in our preferred model).  
One result is that as shown in Table 5 the standard error around our second-stage estimate is 
almost twice as large as with our preferred model.  In any case the point estimate is still 
statistically significant, and slightly larger compared to the preferred model (-.085 versus -.05).
26 
Implicit in our IV design is the notion that there is some “usual” way that new drugs are 
approved and sold within a country.  Consistent with this assumption we find that the adoption 
lags across the OECD countries in our sample for our four instrument drugs are all highly 
                                                 
26 With the simpler linear instrument the second-stage estimates are also sometimes more sensitive to changes in the 
sample or model specification.  For instance if we drop controls for population age structure from the model with the 
linear instrument setup the size of the second-stage point estimate for SSRI sales is hardly affected (-.076 versus -
.085), but the standard error increases substantially (from -.034 to -.056) and so the second-stage estimate is no 
longer statistically significant. 
  27correlated (between +.8 and +.9).  If we regress actual sales values for our instrument drugs 
against one another using our panel of country-level data the R-squared values are usually on the 
order of .5 to .6.  Another way to see this is by constructing new versions of our instruments that 
use separately each of the four instrument drugs (Statins, CCBs, ACEs and PPIs).  The first 
column of Table 5 shows that in our full sample the estimates using Statins, ACEs, and PPIs 
range from -.03 to -.045, close to our preferred IV estimate of -.05.  The outlier comes from 
using CCBs alone to construct our instruments, which seems to be driven in part by the fact that 
CCBs were a smash success in Japan, with CCB sales levels that are much higher than in any 
other country (and also much higher than those of our other drugs in Japan for that matter).  CCB 
sales will thus have more limited power to explain growth in SSRI sales because Japan has 
unusually high CCB sales but unusually low SSRI sales (given its late adopter status).  When we 
restrict our sample to just OECD countries (column 2 of Table 5), the Japan effect in distorting 
the first stage with the CCB instruments is even more pronounced. 
D. Additional Specification Tests 
Perhaps the main concern with our IV estimates is the possibility that countries where 
new drug sales generally increase more rapidly also experience more pronounced improvements 
in other health services or health characteristics compared to slow-drug-sales countries.  One 
way we try to address this concern is to include in our baseline specification both country fixed 
effects and country-specific linear trends, but this may be an imperfect fix. 
One way to address this general concern is to examine whether our IV design suggests a 
relationship between predicted SSRI sales and other causes of death that should not be causally 
affected by SSRI treatment.  This sort of falsification test might be more informative still if we 
focus on causes of death that should also not be substantially affected by drug treatments of any 
  28type, since our basic IV design comes from comparing countries with relatively high and low 
rates of growth in new drugs more generally.  One natural candidate is accidents, which are 
substantially affected by changes in individual behavior and non-medical technologies 
(automotive and transport safety, workplace safety) rather than changes in drug treatments.  The 
estimated coefficient for the “effect” of SSRI sales on the log of accident mortality rates is equal 
to -.0108 (se=.0269), which is not statistically significant and much smaller in absolute value 
than our estimate for the effect of SSRIs on suicide. 
Another falsification check for the validity of our IV design is to examine whether 
countries that are predicted to have high- versus low rates of growth in SSRI sales experience 
different suicide trends before SSRI use became widespread in the 1990s.  The top panel of 
Figure 6 shows there is almost no relationship between the predicted growth in SSRI sales for 
our countries during the period 1990-95 when SSRI use became common with the rate of change 
in log suicide rates during the previous period from 1980-90 (the slope of the regression line is 
equal to -.005).  In contrast there is a pronounced negative relationship between the change in log 
suicide rates from 1990-95 with the predicted change in SSRI sales over this period (the slope is 
-.04, quite close to our formal IV estimate, and significant at the usual cutoff).
27 
While these two falsification checks provide at least some reassurance that our IV 
estimates are not being driven by differences across countries in general improvements to their 
health systems, a more subtle concern arises from the possibility of confounding with trends in 
sales of other anti-depressant drugs besides SSRIs.  Specifically TCA anti-depressant drugs were 
on the market in most countries for decades before the introduction of SSRIs.  In addition in the 
mid to late 1990s another class of anti-depressants was introduced, the serotonin-norepinephrine 
                                                 
27 If we regress change in log suicide rates 1980-85 against change predicted SSRI sales 1990-95 the coefficient is 
equal to -.012, while using as the dependent variable the 1985-90 change in log suicide rates the coefficient is +.009.  
  29reuptake inhibitors (SNRIs), which as their name suggests act on two neurotransmitters 
(serotonin and norepinephrine) rather than just one as with SSRIs.   
There are several reasons to believe that our IV estimates are not confounding the effects 
of SSRI sales with those of either TCAs or SNRIs.  First, Figure 7 shows that SSRI sales account 
for most of the global increase in anti-depressant sales over the period from 1995 (the first year 
for which we could obtain global antidepressant sales figures) to 2004.  Ludwig and Marcotte 
[2005] show that TCA sales were relatively flat in the U.S., and the same appears to be true 
worldwide given little trend in non-SSRI anti-depressant sales in Figure 7 until the late 1990s 
when SNRI sales began to increase.  Changes in SNRI sales are unlikely to be driving our IV 
estimates for the effects of SSRIs in part because they do not represent a major technological 
change in the treatment of depression compared to SSRIs.  But more importantly Figure 7 shows 
that SNRI sales did not begin to substantially increase until the late 1990s, while Table 5 shows 
that our IV estimates for the effects of SSRIs on suicide are not much affected by using data only 
through 1997.  Another way to see this comes from re-estimating our model dropping country-
year observations in which SSRIs accounted for less than 90 percent of total anti-depressant 
sales.
28  The point estimate and standard error (-.0514, 0.190) are similar to our baseline model. 
E. Extensions 
  Much of the concern about SSRI use by government regulators has focused on age 
heterogeneity in drug impacts, since the initial UK and US warnings focused on pediatric use of 
these drugs.  Unfortunately we cannot obtain country-level data on SSRI sales for demographic 
subgroups defined by either gender or age.  However we can at least measure suicide rates 
separately for these subgroups.  Regressing country-level SSRI sales against age-specific suicide 
                                                 
28 On average for the countries in our sample SSRIs accounted for 96.5 percent of antidepressant sales even after 
2000.  A small number of countries saw the market share of SSRIs fall below 90 percent, to 86 percent by 2001 (the 
U.S., the U.K., Norway, Spain, Mexico, Japan, and Australia). 
  30mortality rates will identify the age-specific impacts under the perhaps strong assumption that 
the relative trends across countries in SSRI sales are similar for all age groups and by gender.  
This assumption may not hold in practice, so our sub-group estimates should be taken as only 
suggestive.  Nevertheless given the limitations of RCTs in their ability to identify SSRI impacts 
on suicide mortality we think even these exploratory results might be of some policy value. 
With these important caveats in mind, Table 6 shows that the IV point estimates are 
larger in proportional terms for females than males, although since the baseline suicide mortality 
rate in our data is about three times as high for males as for females (Table 1) the estimated 
association between SSRIs and suicide in absolute terms (deaths per 100,000) will be somewhat 
larger for males than females.  When we disaggregate the suicide data by age, we find the 
estimated relationship between SSRI sales and suicide mortality is largest in both proportional 
and absolute terms for people ages 15-24, consistent with evidence that the largest increase in 
antidepressant prescriptions at least in the U.S. has been among adolescents and young people 
[Zito et al., 2003; American Academy of Adolescent and Child Psychiatry, 2001]. 
VI. CONCLUSIONS 
Understanding the effects of SSRI antidepressants on suicide is important for government 
regulators as well as for doctors, patients, and the family and friends of those suffering from 
severe depression.  It is unlikely that randomized clinical trials (RCTs) will ever be able to 
identify the effects of SSRIs on suicide mortality, both because of small samples and because 
these samples exclude those at highest risk for suicide.  Previous clinical trials instead focus on 
measures of non-lethal “suicidal behavior,” but the association between these indicators and 
actual suicide mortality remains unclear.  Moreover the conditions under which subjects in RCTs 
  31use SSRI drugs (for example level of physician monitoring) may differ from the usual 
community standard of care. 
In light of these practical and ethical constraints, we must turn to population-based 
observational studies to adequately identify the effects of SSRIs on suicide completion rates. We 
believe our study represents a substantial improvement over previous research by using 
population-level data together with a plausibly exogenous source of identifying variation in SSRI 
use.  Specifically we use just the variation in SSRI sales across countries over time that can be 
explained by how quickly these countries adopt new drugs in general, and the rate at which sales 
increase for these new drugs once they are on the market. 
Our results are consistent with the hypothesis that the net effect of the introduction and 
subsequent sales of SSRIs is to reduce death by suicide.  We find that increase in SSRI sales of 1 
pill per capita per year (about a 12% increase over 2000 sales levels) is associated with a decline 
in suicide mortality of around 5%.  This IV estimate is about twice as large in absolute value as 
OLS estimates, consistent with our general concern that both the timing of SSRI approval and 
the rate at which SSRI sales increase over time may be endogenous to what is happening with 
mental health and suicide within countries.  We also demonstrate that that we estimate no 
relationship between SSRI sales and accident deaths, which should not be affected by SSRI use, 
and that there is little relationship between trends across countries in log suicide rates over the 
course of the 1980s and predicted SSRI sales growth in the 1990s. 
Note that the impact we estimate here is the average effect from expanding SSRI sales in 
our sample of countries during the years after these drugs were first introduced to the public.  If 
SSRI treatment went first to those who would benefit the most, or if markets are now becoming 
saturated, additional expansions of SSRI sales may have somewhat smaller impacts on suicide 
  32mortality than our IV estimates would suggest.  However it is possible the difference between the 
average effect implied by our estimates and the effects arising from further expansions in SSRI 
use might be modest, given the relatively low rates of current mental health treatment even in 
very wealthy countries like the U.S. 
Our estimates suggest that on balance SSRIs may be a very cost-effective means for 
saving lives, which is important in part because data from the National Comorbidity Survey from 
2001-3 suggest that only around 40 percent of people with severe mental health disorders were 
receiving any treatment [Kessler, Demler et al., 2005].  Commonly used SSRIs can currently be 
obtained in the United States for around $0.10 per pill.  Our estimates thus imply that each 
additional $20,000 spent on SSRIs will avert one suicide completion, far below the cost per life 
saved from most other public health, regulatory, or other forms of government intervention.  But 
using this estimate in a more formal benefit-cost analysis raises difficult conceptual and 
normative questions about the appropriate way to value the life of someone who subjectively 
prefers death (at least at the time of the intervention).  If SSRIs reduce the risk of suicide by 
reducing access to a method of self harm, then the suicidal person may or may not experience a 
switch to SSRIs as a net benefit, depending on the transience or permanence of their state of 
pain.  On the other hand if SSRIs reduce the risk of suicide by improving the subjective utility of 
life, then persons at risk for suicide and their loved ones may have a considerable willingness to 
pay for such an intervention.
29  Of course SSRIs also generate other benefits beyond their net 
effects on mortality that should be counted in this calculus, including improvements in mood, 
health status, functioning, and productivity. 
                                                 
29 Another complication arises from the possibility that those effectively treated this year may attempt suicide at 
some point in the future.  While the data here are not as strong as we would like there is some suggestion in the 
literature that many persons treated for an episode of major depression do not have recurring episodes. 
  33One important limitation of our study is that we are estimating the average effect of 
expansions in SSRI use on overall suicide mortality rates.  Previous medical studies have raised 
special concerns about drug impacts on certain patient sub-groups.  We provide suggestive 
evidence that the effects of SSRI use on suicide mortality might have, if anything, even more 
beneficial impacts for younger people (15-24), the age group that has been a particular focus of 
recent government warnings in the U.S. and U.K.  However this finding should be qualified by 
the observation that we can measure suicide mortality separately for specific age groups but we 
cannot disaggregate by age country-level sales of SSRIs.  Moreover our data are not at all 
informative about sub-group effects on patients by pre-existing mental health status, which is 
important in light of the view by some researchers that any effect of SSRIs to worsen mood 
might be particularly pronounced among some patients – for example, those with undiagnosed 
bipolar disorder.  Understanding more about heterogeneity in SSRI effects on different types of 
patients remains arguably the top priority for future research in this area. 
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NOTES:   Y-axis presents drug sales (doses per capita), while x-axis shows year.  White bars in each graph show 
instruments from preferred IV model, gray bars show actual SSRI sales, and dark lines show predicted SSRI sales 
values from a simplified version of our first-stage equation that regresses actual SSRI sales against the instruments 
but without the country and year fixed effects, country-specific linear trends and other covariates that are included in 
the actual 2SLS estimation that is used in calculating our preferred IV estimates below.  We show predicted values 
from this simplified first stage equation simply to help illustrate the intuition behind our research design. 
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Figure 5: Predicted Change SSRI Sales from Preferred IV Model vs.  
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 Figure 6: 
Falsification Check, Changes in Suicides Pre and Post SSRI Changes 
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Table 1: Descriptive Statistics for Full Sample of Country-Level Panel Dataset 
Variable Mean  Standard  Deviation 
Full sample (1980-2000) 
SSRI doses per capita 
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NOTES:  Authors’ calculations from WHO mortality and SSRI sales data for sample countries (see text).  Calculations are weighted 
by country population. a = GDP per capita adjusted for changes over time across countries in currency exchange rates. 
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Table 2: Information on SSRIs and other Top Selling Pharmaceutical Classes  
Drug class  Drug purpose  Year first sold  Country first sold 




Proton pump inhibitors  Ulcers  1988  Netherlands 
Calcium channel blockers  Hypertension  1982  US, Spain, Italy, 
Finland, Australia, 
Canada and Ireland 
ACE inhibitors  Hypertension  1982  Canada, Portugal, 
Australia and France 
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Table 3 
OLS Regression Estimates with Country-Level Panel Data 1980 to 2000 
 
  Outcome measure = 
log(suicides/100,000) 
Outcome measure = 
log(suicides/100,000) 
Outcome measure = 
log(suicides/100,000) 
Outcome measure = 
log(suicides/100,000) 
 
SSRI doses sold per capita  -.0350 (.0074)**  -.0258 (.0011)**  -.0198 (.0102)*  -.0204 (.0094)** 
Population age distribution      
% pop 15-24    .0305 (.0254)  .0007 (.0221)  .0006 (.0203) 
% pop 25-34    .0297 (.0187)  .0275 (.0224)  .0218 (.0201) 
% pop 35-44    .0287 (.0143)**  .0087 (.0212)  -.0061 (.0184) 
% pop 45-54    .0025 (.0291)  -.0298 (.0251)  -.0159 (.0218) 
% pop 55-64    .0072 (.0231)  .0535 (.0242)**   .0556 (.0217)** 
% pop 65 and over    .0059 (.0214)  .0130 (.0259)  .0268 (.0254) 
ICD-10 system used to classify 
mortality codes 
  -.0079 (.0422)  -.0417 (.0252)  -.0279 (.0238) 
Indicators for Years Before SSRIs 
on the market: 
    
1  year  before     -.0309  (.0194) 
2  years  before     -.0625  (.0416) 
3  years  before     -.0846  (.0443)* 
4  years  before     -.0994  (.0410)** 
5  years  before     -.0867  (.0353)** 
Model specification      
Year  indicators?  Yes Yes Yes Yes 
Country  indicators?  Yes Yes Yes Yes 












NOTES:  Table reports least squares regression coefficients. Standard errors in parentheses.  Regression models also include a constant intercept term and in the 
last three columns binary indicators for whether GDP, divorce and unemployment rate variables are missing and set equal to zero. Country populations used as 
weights.  For more details on estimation approach see text. * = p<.10 ** = p<.05    
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Table 4 
First and Second Stage Instrumental Variables Estimates  
 
   
Outcome measure = 
SSRI sales per capita 
 
Outcome measure = 
log (suicides/100,000) 
 
SSRI doses sold per capita   -.0542  (.0190)** 
Instruments: Predicted Drug Sales    
Year 1  .4815 (.15627)**   
Year 2  .3613 (.1283)**   
Year 3  .3566 (.1769)**   
Year 4  .3034 (.1534)*   
Year 5  .2866 (.1293)**   
Year 6  .2757 (.1278)**   
Year 7  .2523 (.1285)*   
Year 8  .2845 (.1246)**   
Year 9  .2765 (.1224)**   
Year 10  .3461 (.1094)**   
Year 11  .3942 (.1112)**   
Year 12  .4013 (.1062)**   
Year 13  .3799 (.0985)**   
Year 14  .3985 (.1131)**   
Year 15  .5312 (.1181)**   
% Pop 15-24   .1867 (.1233)  -.0010 (.0196) 
% Pop 25-34  -.5009 (.1693)**  -.0111 (.0280) 
% Pop 35-44  -.2821 (.2909)   .0199(.0347) 
% Pop 45-54   .4729 (.2487)*   .0264 (.0282) 
% Pop 55-64  -.1292 (.2786)   .0524 (.0361) 
% Pop 65 +   -.2096 (.3346)  -.0307 (.0391) 
ICD-10 system to code mortality 
causes 
-1.5687 (.7415)**  .0412 (.0549) 
Model specification    
Year indicators?  Yes  Yes 
Country indicators?  Yes  Yes 
Country-specific linear trends?  Yes  Yes 
F test on joint significance of 
instruments in first stage 








Hausman test of endogeneity of 
SSRI sales  (t-statistic) 
1.64 (p =0.11) 
 
 
NOTES:  Table reports least squares regression coefficients. Standard errors in parentheses.  Regression models also include a 
constant intercept term and binary indicators for whether GDP, divorce and unemployment rate variables are missing and set equal 
to zero. Country populations used as weights.  For more details on estimation approach see text. * = p<.10 ** = p<.05    
 
 Table 5: Sensitivity Analyses 
Model Specification  Full sample  OECD countries only 
Baseline specification  -.0542 (.0190)**  -.0499 (.0178)** 
Drop US  -.0975 (.0383)**  -.0665 (.0252)** 
Drop Mexico  -.0745 (.0238)**  -.0770 (.0227)** 
Drop US and Mexico  -.1475 (.0473)**  -.0917 (.0580) 
Drop Japan and Mexico  -.0601 (.0190)**  .0191 (.0184) 
Drop obs with imputed sales  -.0503 (.0168)**  -.0496 (.0176)** 
No time-varying covariates  -.0408 (.0161)**  -.0319 (.0112)** 
Control for unemployment rate  -.0509 (.0191)**  -.0521 (.0182)** 
Control for real per capita GDP
a  -.0513 (.0173)**  -.0318 (.0171)** 
Control for unemployment and real per 
capita GDP
a 
-.0515 (.0167)**  -.0353 (.0177)** 
 
Restrict sample to ≤ 1997  -.0464 (.0173)**  -.0353 (.0210)* 
Unweighted  -.0442 (.0269)  -.0307 (.0273) 
Not logged  -.2404 (.2070)  -.2973 (.3001) 
Use single linear version of drug sales 





Just use Statin sales data to construct 
instrument 
-.0454 (.0142)**  -.0303 (.0197) 
Just use CCB sales data to construct 
instrument 
.0100 (.0264)  .0494 (.0273)* 
Just use ACE sales data to construct 
instrument 
-.0300 (.0212)  -.0078 (.0186) 
Just use PPI sales data to construct 
instrument 
-.0337 (.0184)**  -.0077 (.0268) 
 
NOTES: a = Figures for real per capita GDP adjusted for exchange rate variation over time.  Each cell includes the coefficient for 
predicted SSRI sales values by applying the basic IV estimation approach as in Table 4 (from equations 4 and 5 in the text) to the 
analytic sample described at the top of the column, with deviations from the basic model setup described at left for each row.  
Robust standard errors are in parentheses, clustered at the country level to account for serial correlation.  * = p<.1, ** = p<.05 
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on Suicide Mortality for Population Sub-Groups 
Dependent variable  Full sample  OECD countries only 
Log suicide, females  -.0775 (.0174)**  -.0937 (.0184)** 
Log suicide, males  -.0539 (.0215)**  -.0483 (.0214)* 
Log suicide, age 15-24  -.0978 (.0275)**  -.0849 (.0556) 
Log suicide, age 25-34  -.0525 (.0226)**  -.0326 (.0341) 
Log suicide, age 35-44   .0000 (.0303)   .0223 (.0306) 
Log suicide, age 45-54  -.0171 (.0305)  -.0249 (.0251) 
Log suicide, age 55-64  -.0398 (.0318)  -.0228 (.0317) 
Log suicide, age 65 +  -.0253 (.0394)  -.0145 (.0335) 
 
NOTES: Each cell includes the coefficient for predicted SSRI sales values by applying the basic IV estimation approach as in Table 
4 (from equations 4 and 5 in the text) to the analytic sample described at the top of the column, with the dependent variable of 
interest described at left for each row.  Robust standard errors are in parentheses, clustered at the country level to account for serial 
correlation.  * = p<.1, ** = p<.05 
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